Journal of Antimicrobial Chemotherapy (2000) 45, 225-230
© 2000 The British Society for Antimicrobial Chemotherapy
Brief reports |
Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom
Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London NW9 5HT, UK
The in vitro activity of linezolid, an oxazolidinone, was assessed against 374 Gram-positive cocci, with an emphasis on testing multi-resistant, epidemiologically unrelated isolates. MICs of linezolid for staphylococci, pneumococci and streptococci had a narrow range, from 0.5 to 2 mg/L, whereas MICs for enterococci were uniformly 4 mg/L. For all the species tested, the MICs of linezolid were unrelated to those of other antimicrobials. Linezolid appears to be a potentially useful drug for infections caused by Gram-positive cocci.
* Corresponding author. Tel: +44-181-200-4400, ext. 4237; Fax: +44-181-200-7449; E-mail: ajohnson{at}phls.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J I Prydal, D R Jenkins, A Lovering, and A Watts The pharmacokinetics of linezolid in the non-inflamed human eye Br J Ophthalmol, November 1, 2005; 89(11): 1418 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Yong, J. H. Yum, K. Lee, Y. Chong, S. H. Choi, and J. K. Rhee In Vitro Activities of DA-7867, a Novel Oxazolidinone, against Recent Clinical Isolates of Aerobic and Anaerobic Bacteria Antimicrob. Agents Chemother., January 1, 2004; 48(1): 352 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Smith, M. C. Birmingham, G. A. Noskin, A. K. Meagher, A. Forrest, C. R. Rayner, and J. J. Schentag Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia Ann. Onc., May 1, 2003; 14(5): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rana, I. Butcher, P. Grigoris, C. Murnaghan, R. A. Seaton, and C. M. Tobin Linezolid penetration into osteo-articular tissues J. Antimicrob. Chemother., November 1, 2002; 50(5): 747 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Baum, S. A. Crawford, M. L. McElmeel, C. G. Whitney, and J. H. Jorgensen Comparative Activities of the Oxazolidinone AZD2563 and Linezolid against Selected Recent North American Isolates of Streptococcus pneumoniae Antimicrob. Agents Chemother., September 1, 2002; 46(9): 3094 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Fluit, F.-J. Schmitz, J. Verhoef, and D. Milatovic In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci J. Antimicrob. Chemother., August 1, 2002; 50(2): 271 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, M. Warner, and D. M. Livermore In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci J. Antimicrob. Chemother., July 1, 2002; 50(1): 89 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gentry-Nielsen, K. M. Olsen, and L. C. Preheim Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1345 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gander, K. Hayward, and R. Finch An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model J. Antimicrob. Chemother., February 1, 2002; 49(2): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Ho, T. K. Ng, R. W. H. Yung, T. L. Que, E. K. T. Yip, C. W. S. Tse, and K. Y. Yuen Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong J. Antimicrob. Chemother., October 1, 2001; 48(4): 590 - 592. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore, S. Mushtaq, and M. Warner Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints': J Antimicrob Chemother 2001; 48: 452-454 J. Antimicrob. Chemother., September 1, 2001; 48(3): 452 - 454. [Full Text] [PDF]
|
|
|
|
|
|
A. Hallgren, H. Abednazari, C. Ekdahl, H. Hanberger, M. Nilsson, A. Samuelsson, E. Svensson, L. E. Nilsson, and t. Swedish ICU Study Group Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems J. Antimicrob. Chemother., July 1, 2001; 48(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tubau, R. Fernandez-Roblas, J. Linares, R. Martin, and F. Soriano In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods J. Antimicrob. Chemother., May 1, 2001; 47(5): 675 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Henwood, D. M. Livermore, A. P. Johnson, D. James, M. Warner, A. Gardiner, and The Linezolid Study Group Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid J. Antimicrob. Chemother., December 1, 2000; 46(6): 931 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother., September 1, 2000; 46(3): 347 - 350. [Full Text] [PDF]
|
|